Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

Breast cancer is the most common malignancy in women all over the world. Genetic background of women contributes to her risk of having breast cancer. Certain inherited DNA mutations can dramatically increase the risk of developing certain cancers and are responsible for many of the cancers that run in some families. Regarding the widespread multigene panels, whole exome sequencing is capable of providing the evaluation of genetic function mutations for development novel strategy in clinical trials. Targeting the mutant proteins involved in breast cancer can be an effective therapeutic approach for developing novel drugs. This systematic review discusses gene mutations linked to breast cancer, focusing on signaling pathways that are being targeted with investigational therapeutic strategies, where clinical trials could be potentially initiated in the future are being highlighted.

• Publication year

  2019

• Venue

  Journal of Hematology & Oncology

• Publication date

  2019-04-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13045-019-0725-6PMID 30975222PMCID 6460547
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MRN (MRE11-RAD50-NBS1) Complex in Human Cancer and Prognostic Implications in Colorectal Cancer

  2019cited by this paper
• Faculty Opinions recommendation of Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.

  2019cited by this paper
• A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.

  2019cited by this paper
• A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN

  2019cited by this paper
• Patterns of Genomic Instability in Breast Cancer.

  2019cited by this paper
• Heart rate variability in normal tension glaucoma

  2018cited by this paper
• BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer

  2018cited by this paper
• Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.

  2018cited by this paper
• The Androgen Receptor in Breast Cancer

  2018cited by this paper
• BRCA1/2 testing: therapeutic implications for breast cancer management

  2018cited by this paper
• Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

  2018cited by this paper
• Overexpression of the MRE11-RAD50-NBS1 (MRN) complex in rectal cancer correlates with poor response to neoadjuvant radiotherapy and prognosis

  2018cited by this paper
• Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

  2018cited by this paper
• Genetic Modifiers of the Breast Tumor Microenvironment.

  2018cited by this paper
• Androgen blockade based clinical trials landscape in triple negative breast cancer.

  2018cited by this paper
• Novel molecular insights and new therapeutic strategies in osteosarcoma

  2018cited by this paper
• Value of Physical Examination in the Diagnosis of Developmental Hip Dislocation in Preterm Infants

  2018cited by this paper
• Recent Advances in the Treatment of Breast Cancer

  2018cited by this paper
• Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review.

  2018cited by this paper
• Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

  2018cited by this paper
• Progress in targeted therapy for breast cancer

  2018cited by this paper
• Cancer genetics, precision prevention and a call to action

  2018cited by this paper
• Current perspectives on CHEK2 mutations in breast cancer

  2017cited by this paper
• Coupling of Homologous Recombination and the Checkpoint by ATR.

  2017cited by this paper
• Targeted therapies in breast cancer: New challenges to fight against resistance

  2017cited by this paper
• Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083

  2017cited by this paper
• Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?

  2017cited by this paper
• Association analysis identifies 65 new breast cancer risk loci

  2017cited by this paper
• The Role of PALB2 in the DNA Damage Response and Cancer Predisposition

  2017cited by this paper
• Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  2017cited by this paper
• Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer

  2017cited by this paper
• Assessment of the Kidney Size in Newborns

  2017cited by this paper
• Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells.

  2017cited by this paper
• RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non–small Cell Lung Cancer

  2017cited by this paper
• A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

  2017cited by this paper
• A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes

  2017cited by this paper
• Dualistic Role of BARD1 in Cancer

  2017cited by this paper
• Two novel STK11 missense mutations induce phosphorylation of S6K and promote cell proliferation in Peutz-Jeghers syndrome.

  2017cited by this paper
• Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 study

  2017cited by this paper
• Integrative Clinical Genomics of Metastatic Cancer

  2017cited by this paper
• Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

  2016cited by this paper
• Hereditary breast and ovarian cancer: new genes in confined pathways

  2016cited by this paper
• CDH1 germline mutations and hereditary lobular breast cancer

  2016cited by this paper
• Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

  2016cited by this paper
• COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo

  2016cited by this paper
• The kinome 'at large' in cancer

  2016cited by this paper
• Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

  2016cited by this paper
• Androgen receptor signaling pathways as a target for breast cancer treatment.

  2016cited by this paper
• Inherited Mutations in Women With Ovarian Carcinoma.

  2016cited by this paper
• BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency

  2016cited by this paper
• Molecular Classification of Triple-Negative Breast Cancer

  2016cited by this paper
• Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer

  2016cited by this paper
• The therapeutic potential of mTOR inhibitors in breast cancer.

  2016cited by this paper
• BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin.

  2016cited by this paper
• PARP inhibitors: the race is on

  2016cited by this paper
• Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

  2016cited by this paper
• RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy

  2016cited by this paper
• Abstract P2-09-08: Universal BRCA testing and family outreach for women with triple negative breast cancer

  2016cited by this paper
• High Expression of MRE11-RAD50-NBS1 Is Associated with Poor Prognosis and Chemoresistance in Gastric Cancer.

  2016cited by this paper
• Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication.

  2016cited by this paper
• A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

  2016cited by this paper
• Targeting the androgen receptor in triple-negative breast cancer.

  2016cited by this paper
• New concepts on BARD1: Regulator of BRCA pathways and beyond.

  2016cited by this paper
• Health risks for ataxia‐telangiectasia mutated heterozygotes: a systematic review, meta‐analysis and evidence‐based guideline

  2016cited by this paper
• ATM Mutations in Cancer: Therapeutic Implications

  2016cited by this paper
• No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

  2016cited by this paper
• Nuclear factor I-C regulates E-cadherin via control of KLF4 in breast cancer

  2015cited by this paper
• ATM and ATR as therapeutic targets in cancer.

  2015cited by this paper
• Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling

  2015cited by this paper
• Lobular breast cancer: incidence and genetic and non-genetic risk factors

  2015cited by this paper
• Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases

  2015cited by this paper
• Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example

  2015cited by this paper
• Targeting LKB1 in cancer – exposing and exploiting vulnerabilities

  2015cited by this paper
• Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.

  2015cited by this paper
• Expression of androgen receptor splice variants in clinical breast cancers

  2015cited by this paper
• A mechanism for the suppression of homologous recombination in G1 cells

  2015cited by this paper
• Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway.

  2015cited by this paper
• Germline TP53 mutational spectrum in French Canadians with breast cancer

  2015cited by this paper
• Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

  2015cited by this paper
• HER2-directed therapy: current treatment options for HER2-positive breast cancer

  2015cited by this paper
• Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.

  2015cited by this paper
• Trapping Poly(ADP-Ribose) Polymerase

  2015cited by this paper
• Better Together: Targeted Combination Therapies in Breast Cancer.

  2015cited by this paper
• Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer

  2015cited by this paper
• Mechanisms of lapatinib resistance in HER2-driven breast cancer.

  2015cited by this paper
• Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers

  2015cited by this paper
• Structural perspective of ARHI mediated inhibition of STAT3 signaling: an insight into the inactive to active transition of ARHI and its interaction with STAT3 and importinβ.

  2015cited by this paper
• Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer

  2015cited by this paper
• Notch signaling: an emerging therapeutic target for cancer treatment.

  2015cited by this paper
• HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

  2015cited by this paper
• Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.

  2015cited by this paper
• Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.

  2015cited by this paper
• Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines

  2014cited by this paper
• Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.

  2014cited by this paper
• A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype

  2014cited by this paper
• TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance

  2014cited by this paper
• Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

  2014cited by this paper
• Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2

  2014cited by this paper
• Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium

  2014cited by this paper

• Evolving Treatments and Resistance Mechanisms in Prostate Cancer Therapeutics

  2026cites this paper
• Therapeutic targeting of post-translational modifications in ovarian cancer: mechanisms and clinical applications

  2025cites this paper
• Sweets consumption and breast cancer risk among women in yemen: a matched case control study

  2025cites this paper
• Genetic Landscape of Familial Melanoma

  2025cites this paper
• Synergistic anticancer effect of Doxorubicin and Tamoxifen in chitosan nanoparticles for ER-positive breast cancer

  2025cites this paper
• DNA damage repair-related methylated genes RRM2 and GAPDH are prognostic biomarkers associated with immunotherapy for lung adenocarcinoma

  2025cites this paper
• Whole-exome sequencing for identification of specific gene mutations in an Indian cohort of triple-negative breast cancer patients

  2025cites this paper
• PTEN-mediated resistance in cancer: From foundation to future therapies

  2025cites this paper
• Identification of DNA damage repair-related genes in sepsis using bioinformatics and machine learning: An observational study

  2025cites this paper
• Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence

  2025influential citation
• Comprehensive insights into pathogenicity and emerging CRISPR-integrated biosensors for the early detection of breast cancer biomarkers

  2025cites this paper
• From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment

  2025cites this paper
• Metabolomic Profiling of Disease Progression Following Radiotherapy for Breast Cancer

  2025cites this paper
• Patient‐Derived Organoids as Therapy Screening Platforms in Cancer Patients

  2024cites this paper
• Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair‐associated signature

  2024cites this paper
• Liposomes for the treatment of prostate cancer therapy: A review.

  2024cites this paper
• Exploring the antiproliferative and proapoptotic activities of new pyridopyrimidine derivatives and their analogs.

  2024cites this paper
• Male Breast Cancer Biology, Screening, Treatment, and Follow-Up: A Narrative Review

  2024cites this paper
• Mapping functional elements of the DNA damage response through base editor screens.

  2024cites this paper
• Gynecologic and breast cancers with hereditary cancer predisposition syndromes

  2024cites this paper
• The VEGFA rs3025039 Variant Is a Risk Factor for Breast Cancer in Mexican Women

  2024influential citation
• A New Genetic Signature of Lactate Metabolism-Associated Genes Predicting Clinically Distinctive Features and Tumor Microenvironment in Colorectal Cancer

  2024cites this paper
• BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review

  2024influential citation
• Potential function of microRNA miRNA-206 in breast cancer pathogenesis: Mechanistic aspects and clinical implications.

  2024cites this paper
• Integrating molecular pathway with genome-wide association data for causality identification in breast cancer

  2024cites this paper
• CRISPR/Cas9-mediated knockout strategies for enhancing immunotherapy in breast cancer

  2024cites this paper
• GLIPR2: a potential biomarker and therapeutic target unveiled – Insights from extensive pan-cancer analyses, with a spotlight on lung adenocarcinoma

  2024cites this paper
• Epigenetics as a Key Factor in Prostate Cancer

  2024cites this paper
• Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis

  2023cites this paper
• Association between genetic polymorphisms and risk of adolescent idiopathic scoliosis in case-control studies: a systematic review

  2023cites this paper
• Rate of Pathogenic Germline Variants in Patients With Lung Cancer

  2023cites this paper
• Immunohistochemical Detection of the Expressed BRCA1 and BRCA2 Proteins in Microenvironment of Malignant Breast Cancerous Tissues Infected with Human Mammary Tumor Virus

  2023cites this paper
• Artificial intelligence-driven biomedical genomics

  2023cites this paper
• Exploring the Potential Mechanism of Capsicum against Breast Cancer Based on Network Pharmacology

  2023cites this paper
• On the determinants and the role of the payers in the uptake of genetic testing and data sharing in personalized health

  2023cites this paper
• Estrogen receptor alpha (ESR1) gene polymorphism (rs2234693 and rs2046210) with breast cancer risk in pashtun population of Khyber Pakhtunkhwa

  2023cites this paper
• Identification of a DNA Damage Response and Repair-Related Gene-Pair Signature for Prognosis Stratification Analysis in Hepatocellular Carcinoma

  2022cites this paper
• Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers

  2022cites this paper
• Cytotoxicity of Mahanimbine from Curry Leaves in Human Breast Cancer Cells (MCF-7) via Mitochondrial Apoptosis and Anti-Angiogenesis

  2022cites this paper
• State-of-the-art Cancer Biomarker Detection by Portable (Bio) Sensing Technology: A Critical Review

  2022cites this paper
• Sequencing of BRCA1/2-alterations using NGS-based technology: annotation as a challenge

  2022cites this paper
• Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.

  2022cites this paper
• "Residential Exposure to Power Plants as a Potential Breast Cancer Risk Factor: A report of Miguel Aleman, Sonora, Mexico"

  2022cites this paper
• A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer

  2022cites this paper
• Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer

  2022cites this paper
• Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview

  2022cites this paper
• A New View of Activating Mutations in Cancer

  2022cites this paper
• Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches

  2022cites this paper
• Designing a humanized immunotoxin based on DELTA-stichotoxin-Hmg2a toxin: an in silico study

  2022cites this paper
• Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature).

  2021cites this paper
• Starring role of Biomarkers and Anticancer Agents as a Major Driver in Precision Medicine of Cancer Therapy.

  2021cites this paper
• Anti-breast cancer synthetic peptides derived from the Anabastestudineus skin mucus fractions

  2021cites this paper
• Potential role of BRCA1 protein expression as a prognostic tissue biomarker in breast carcinoma: An immunohistochemical and clinicopathologic study from South India

  2021cites this paper
• Microbiome Assisted Tumor Microenvironment: Emerging Target of Breast Cancer.

  2021cites this paper
• Genetic variants associated with the occurrence and progression of adolescent idiopathic scoliosis: a systematic review protocol

  2021cites this paper
• Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer

  2021cites this paper
• Integrated Analyses Reveal the Multi-Omics and Prognostic Characteristics of ATP5B in Breast Cancer

  2021cites this paper
• Systematic integrated analyses of methylomic and transcriptomic impacts of early combined botanicals on estrogen receptor-negative mammary cancer

  2021cites this paper
• The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology

  2021cites this paper
• Substitutions of the NBS1 gene and clinicopathological characteristics of young breast cancer patients

  2021cites this paper
• T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches

  2021cites this paper
• Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer

  2021cites this paper
• Classification Tree-Based Machine Learning to Visualize and Validate a Decision Tool for Identifying Malnutrition in Cancer Patients.

  2021cites this paper
• Mass spectrometry-based targeted proteomics for analysis of protein mutations.

  2021cites this paper
• 1 BARD 1 and breast cancer : the possibility of creating 2 screening tests and new preventive and therapeutic 3 pathways for predisposed women 4

  2020cites this paper
• Molecular Cytogenomic Characterization of the Murine Breast Cancer Cell Lines C-127I, EMT6/P and TA3 Hauschka

  2020cites this paper
• Effect arylamine N-acetyltransferase 1 on morphology, adhesion, migration, and invasion of MDA-MB-231 cells: role of matrix metalloproteinases and integrin αV

  2020cites this paper
• Synthesis, Characterisation and Cytotoxicity of Gold Nanowires for Ultra-Sensitive Biosensor Development

  2020cites this paper
• Inhibition of DOT1L by Half-Selenopsammaplin A Analogs Suppresses Tumor Growth and EMT-Mediated Metastasis in Triple-Negative Breast Cancer

  2020cites this paper
• Synthesis, characterisation and cytotoxicity of gold microwires for ultra-sensitive biosensor development

  2020cites this paper
• [Hereditary cancer syndromes: a modern paradigm].

  2020cites this paper
• A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma

  2020cites this paper
• BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.

  2020cites this paper
• BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women

  2020cites this paper
• Overexpression of RAD50 is the Marker of Poor Prognosis and Drug Resistance in Breast Cancer Patients.

  2020cites this paper
• Exploring the effects of genetic variation on gene regulation in cancer in the context of 3D genome structure

  2020cites this paper
• Precision Medicine: Steps along the Road to Combat Human Cancer

  2020cites this paper
• The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients.

  2020cites this paper
• Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.

  2020cites this paper
• VA National Precision Oncology Program.

  2020cites this paper
• Long Non-Coding RNA THOR Enhances the Stem Cell-Like Traits of Triple-Negative Breast Cancer Cells Through Activating β-Catenin Signaling

  2020cites this paper
• Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer.

  2020cites this paper
• Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine

  2020cites this paper
• RNA-sequencing and microarray data mining revealing: the aberrantly expressed mRNAs were related with a poor outcome in the triple negative breast cancer patients

  2020cites this paper
• Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer

  2020cites this paper
• Long Non-Coding RNA NEAT1 Promotes the Proliferation, Migration, and Metastasis of Human Breast-Cancer Cells by Inhibiting miR-146b-5p Expression

  2020cites this paper
• Early Steps of Mammary Stem Cell Transformation by Exogenous Signals; Effects of Bisphenol Endocrine Disrupting Chemicals and Bone Morphogenetic Proteins

  2019cites this paper
• Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells.

  2019cites this paper
• Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer.

  2019cites this paper
• MRN (MRE11-RAD50-NBS1) Complex in Human Cancer and Prognostic Implications in Colorectal Cancer

  2019cites this paper
• A Potential New Mechanism for Bisphenol Molecules to Initiate Breast Cancer through Alteration of Bone Morphogenetic Protein Signaling in Stem Cells and Their Microenvironment

  2019cites this paper